Archive: News
-
Underuse of exon mutational analysis for gastrointestinal stromal tumors
Increased use of EMA will improve clinical outcomes in both current and future patients by informing treatment plans and identifying new, potential therapeutic targets as the role of genetics in medicine continues to expand.
Category: News
-
Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) remains the most aggressive malignancy with the lowest 5-year survival rate of all cancers in part owing to the lack of tumor-specific therapy and the rapid metastatic nature of this cancer.
Category: News
-
Expert Highlights Long-Lasting Benefits of Pembrolizumab for Patients With GI Cancers
Pembrolizumab (Keytruda), for example, has induced durable responses in certain subsets of patients with gastric and colorectal cancer (CRC), but many patients still do not respond to this type of therapy.
Category: News
-
Marshall Highlights Durable Benefits of Pembrolizumab in GI Cancers
Immunotherapy has arrived in the gastrointestinal cancer landscape, and while not all patients will benefit from these agents, those who do are likely to have long-lasting responses, explained John L. Marshall, MD.
Category: News
-
Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
TML-high rate varied widely among gastrointestinal cancers. Although MSI is conceivably the main driver for TML-high, other factors may be involved.
Category: News
-
Immuno‐Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD‐L1 Testing May Not Be Enough
PD-L1 testing alone fails to detect patients who may benefit from ICI. Lower PD-L1 thresholds and TML testing should be considered in future clinical trials.
Category: News
-
The American Association for Cancer Research and No Stomach For Cancer Partner to Offer a Gastric Cancer Research Fellowship
Julian Burks, PhD, a postdoctoral research fellow at Georgetown University, has been selected as the first recipient of the AACR-No Stomach For Cancer Gastric Cancer Research Fellowship.
Category: News
-
Genetic Testing Is Important for Both Patients and Family Members
The understanding of genetic mutations, like tumors that are microsatellite instability-high (MSI-H), and the therapies that go along with them is transforming the world of colorectal cancer, according to John Marshall, M.D.
Category: News
-
Woman mistook her stomach symptoms for food poisoning, warns about risk
For two years, 34-year-old Diana Zepeda thought her GI symptoms were caused by stress and diet.
Category: News
-
Dr. John Marshall: Outspoken advocate and expert
On National Doctors’ Day, the Colorectal Cancer Alliance interviewed Dr. John Marshall.
Category: News